Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | AOC3 | Q16853 | 14/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386471 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL2612387 | 0.86 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL9834676 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL5570311 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL9835060 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL4886988 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL11222597 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL10745939 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL3933173 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AAOC3MAOBNPC1 | |
| SCHEMBL9836892 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AAOC3MAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-0574118-A1 | Polycyclic dyes | ZENECA LIMITED (GB) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | SMN1; SMN2 3368/4885KMT2A 1093/4885AOC3 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.